AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application ...

The clearance is a step forward in AstraZeneca and Daiichi Sankyo’s plan to position antibody-drug conjugates like Enhertu ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® ...

Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca PLC securities between February 23, 2022 and December ...

AstraZeneca CFO Aradhana Sarin promised Phase III readouts and revenue growth in 2025 despite ongoing investigations of its Chinese operations. Credit: Bloomberg/ Getty Images AstraZeneca says a ...

Supplementary forms are required for the following schools in addition to the completion of your home local authority application form. The below options link to the individual school's website.

AstraZeneca's first-in-class severe asthma ... and not restricted to those with forms of the disease tied to specific characteristics such as high levels of eosinophils. AZ's head of biopharma ...

AstraZeneca still trades at a premium valuation, but several factors limit its upside potential in the next visible period. There are three negative takeaways from China. IRA could also ...

Online submission of application form 02 January to 01 February 2025 (up to 11:50 P.M.) Last date for successful fee transaction 02 February 2025 (up to 11:50 P.M.) Correction in application ...

The official website for NEET UG 2025 is neet.nta.nic.in. This website will host the online registration-cum-application process and share important details. The National Testing Agency (NTA ...

UK-based pharmaceutical giant AstraZeneca has announced plans to restructure its biopharma unit to concentrate on next-generation therapeutics. “In the Biopharmaceutical Business Unit, we are now ...